Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of CrbnI391V

Multiple myeloma is a genetically heterogeneous malignancy of plasma cells. Current treatments for multiple myeloma comprise proteasome inhibitors, steroids, chemotherapy, antibodies and immunomodulatory drugs (IMiDs) 1-3. However, despite combination of these drugs, multiple myeloma remains incurable in the majority of cases.

Source: Experimental Hematology - November 10, 2020 Category: Hematology Authors: Linda R öhner, Yuen Lam Dora Ng, Annika Scheffold, Stefanie Lindner, Simon Köpff, Andreas Brandl, Andreas Beilhack, Jan Krönke Source Type: research